www.finanznachrichten.de · · DE
68737787 bioinvent international bioinvent s bi 1206 triplet achieves 83 response rate in refractory nhl with improved safety vs soc 200
News Analysis — AI Analysis
Original analysis generated by News Analysis. This is our own commentary on the story, not the publisher's article text.
BioInvent announced new clinical data for its BI-1206 triplet combination (BI-1206 + rituximab + acalabrutinib) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). The regimen achieved an 83% objective response rate (ORR) across the total NHL population and demonstrated a favorable safety profile compared to standard-of-care regimens. These findings were presented at the EHA 2026 Congress, positioning BI-1206 as a potentially significant new treatment option.
Key points
- The BI-1206 triplet combination was tested in a Phase 1/2 study for relapsed or refractory NHL, including follicular lymphoma (FL).
- Key efficacy data included an overall ORR of 83% and an ORR of 81% specifically within the FL subset.
- The regimen showed a significantly improved safety profile, reporting serious adverse events in only 14% of patients compared to much higher rates in comparator groups.
- BI-1206 is designed to target Fc?RIIB-mediated rituximab internalization, addressing a major cause of resistance to CD20-directed therapies.
- The study cohort has been fully enrolled, but further survival data (like PFS) are not yet available.
Claims assessed
- VerifiableThe BI-1206 triplet combination achieved an 83% objective response rate in the total non-Hodgkin's lymphoma population.
- VerifiableThe regimen showed a markedly lower rate of serious adverse events (14%) compared to standard-of-care regimens like R2, which reported rates between 29-56%.
- VerifiableBI-1206 is intended to overcome resistance to CD20-directed therapies by targeting Fc?RIIB-mediated rituximab internalization.
Missing context
While the data is promising, the article notes that PFS (progression-free survival) calculations are premature because most patients are still on treatment. Readers should understand that these results represent current response rates and not long-term outcomes.
Topic context
Related topics
The full article is on the original publisher site.
Related stories
finanznachrichten.de
68738324 curium group peptidream and pdradiopharma announce completion of patient dosing in clinical trial of 64cu psma i t for prostate cancer in japan 399
finanznachrichten.de
68737788 bioinvent international bioinvent s tnfr2 antibody bi 1808 delivers meaningful responses and immune activation as single agent and in combination wit 200
finance.yahoo.com
Broader Market Settles Lower Chip
bigpara.hurriyet.com.tr
yatirimci tcmb ve ecb faiz kararlarina odaklandi ID
rozanaspokesman.com